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Introduction: Stereotactic ablative radiotherapy is a guideline-
recommended treatment for early stage non–small-cell lung 
cancer. We report on incidence and salvage of local recurrences 
(LR) and second primary lung cancers (SPLC) in a large series of 
patients with long-term follow-up, to generate data for evidence-
based follow-up regimens.
Methods: We excluded all patients with double tumors, TNM-stages 
other than T1-T2N0M0, biologically effective dose less than 100 
Gy
10
 and previous treatment for the index tumor from our institu-
tional database. LR was defined as recurrence in/adjacent to the 
planning target volume. A diagnosis of SPLC was determined using 
criteria described by Martini et al.
Results: The 855 patients included had a median follow-up of 
52 months. Forty-six patients developed LR after a median of 22 
months (range 7–87 months). Actuarial local control rates at 3 and 
5 years were 92.4% and 90.9%, respectively. Fifty-four percent had 
isolated LR and 13% had LR in combination with regional recur-
rences. Ten patients underwent radical salvage treatment; surgery 
(N = 6), high-dose radiotherapy (N = 3), or chemoradiation (N = 1). 
Median overall survival following LR was 13 months, but it was 
36 months in patients who underwent radical salvage. A SPLC was 
diagnosed in 79 patients, after a median interval of 34 months. 
Actuarial cumulative incidences of SPLC at 3 and 5 years were 
11.7% and 16.7%, respectively. Radical salvage for SPLC was per-
formed in 63 patients (80%).
Conclusions: Both the timing of LR and persistent risk of SPLC 
serve as rationale for long-term follow-up using computed tomog-
raphy scans in patients fit enough to undergo any radical treatment.
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Stereotactic ablative radiotherapy (SABR) is a guideline-recommended treatment for peripheral early stage non–
small-cell lung cancer (NSCLC) in patients who are unfit for 
surgery.1,2 Although randomized controlled trials comparing 
surgery and SABR in operable patients have failed to accrue 
sufficient numbers of patients, comparative effectiveness 
studies suggest similar outcomes following both treatment 
modalities.3,4 In recent years, a shift in treatment patterns has 
been observed, with SABR increasingly being used in fitter, 
high-risk surgical patients.5,6 In such patients, early recogni-
tion of a local recurrence (LR) or new second primary lung 
cancer (SPLC), which is reported to occur in 3–6% per year, is 
particularly important as they are potentially salvageable.7 In 
patients undergoing surgery for early stage NSCLC, treatment 
of LRs has been shown to be a predictor for postrecurrence 
survival. Therefore, the surgical resection of isolated LRs has 
been recommended.8
In patients treated with SABR for early stage NSCLC, 
clinical practice guidelines of the European Society for 
Medical Oncology recommend computed tomography (CT) 
imaging every 3–6 months for a period of 2–3 years postra-
diotherapy followed by annual CT imaging.1 This advice was 
updated in 2014 to emphasize that CT should also be per-
formed with a frequency of 6 months for at least 3 years in 
those patients suitable for salvage therapy.9 Such recommen-
dations should ideally be based on long-term observational 
studies, but there is limited data available to guide the opti-
mal follow-up frequency and duration after SABR. Similarly, 
there is little known about how many patients are eligible for 
such salvage treatments.
We previously reported on the outcomes after SABR 
in a group of 676 patients, after a median follow-up of 32.9 
months.10 In this article, we updated our series with more 
patients and longer follow-up, and pay specific attention to 
LRs and salvage therapy, to generate data for evidence-based 
follow-up regimens.
MATERIALS AND METHODS
Details of all patients with ES-NSCLC treated with 
SABR between 2003 and 2013 at our center are recorded in 
an institutional database. For this study, we excluded patients 
with synchronous lung tumors, a TNM-stage other than 
T1-T2N0M0 and previous treatment for the index tumor and 
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patients treated with a fractionation scheme with a biologi-
cally effective dose <100 Gy
10
.
As reported previously, SABR was delivered in an out-
patient setting, using risk adapted fractionation schemes to a 
total dose of 60 Gy, with more fractionated schemes for larger 
lesions and tumors near organs at risk.11 All fractionation 
schemes had a biologically effective dose of >100 Gy
10
 pre-
scribed to the planning target volume (PTV).
Posttreatment follow-up generally consisted of contrast-
enhanced CT scans of the thorax and upper abdomen at 3 and 
6 months post-SABR, followed by 6 months until 2 years after 
treatment and annually thereafter. Follow-up was performed 
in our center and/or in the referring center. Where necessary, 
the general practitioner or pulmonologist was contacted to 
retrieve follow-up data.
LRs were defined as a recurrence in, or adjacent to, the 
PTV. A LR was suspected if there was a growing or increas-
ingly dense mass on sequential follow-up CT scans. For this 
analysis, cases where there was persistent uncertainty between 
either LR or post-SABR fibrosis were scored as having a 
recurrence. Identification of high-risk radiological features 
suspicious for recurrence, such as those recently published, 
were not used for identifying LRs in the present cohort, as 
they were published after the study period.9,12 In the event 
of a growing lesion suspicious for a LR, and therefore fol-
lowed up with imaging before a final diagnosis of a LR, we 
dated the recurrence to the date of initial clinical suspicion. 
Locoregional recurrence was defined as a LR, either with or 
without tumor recurrence in regional lymph nodes.
A new, distinct pulmonary tumor was considered a SPLC 
if it fulfilled the criteria for multiple metachronous lung cancers 
described by Martini et al.,13 namely: (A) different histology or 
(B) the same histology if (1) the disease-free interval between 
cancers was at least 2 years, or (2) if the origin was from carci-
noma in situ, or (3) if the second cancer was in a different lobe or 
lung without carcinoma in lymphatics common to both and with 
no extra pulmonary metastases at the time of diagnosis.
Follow-up was calculated using the reverse Kaplan–
Meier method.14 Time-to-event outcomes were analyzed using 
the Kaplan–Meier method. The risks per year were calculated 
using actuarial control rates retrieved from the Kaplan–Meier 
survival tables. Univariate analysis was performed with the log-
rank test to investigate the prognostic value of age, sex, tumor 
stage, fractionation scheme, treatment delivery technique, PTV 
size, presence of a pretreatment pathological diagnosis, histol-
ogy, and a history of a prior (pulmonary) malignancy.
RESULTS
A total of 855 patients with early stage NSCLC fulfill-
ing the above-mentioned inclusion criteria were identified. 
The median follow-up in all patients was 52 months (inter-
quartile range 33–72 months). The major patient characteris-
tics are displayed in Table 1.
In a total of 73 patients (i.e., 8.5% of all patients), a LR 
was suspected at some point during follow-up after review of 
CT scans. Of these, a final diagnosis of a LR was made in 46 
patients by pathology and/or radiology. In the 27 patients in 
whom a recurrence was considered unlikely, this was based 
on a negative fluorodeoxyglucose-positron emission tomogra-
phy (18FDG-PET) scan in 13 patients (48%) and/or a negative 
biopsy in three patients (11%). In another 14 patients, a LR 
was considered to be unlikely based on the subsequent find-
ings of stable or regressing masses on serial CT scans.
In 46 patients with a diagnosis of LR, this diagno-
sis was established at a median of 22 months (range 7–87 
months). The actuarial local control rates at 1-, 3-, and 5 years 
post-SABR were 98.9%, 92.4%, and 90.9%, respectively. 
Univariate analysis was performed in the entire patient cohort 
to identify potential factors influencing local control. None of 
the investigated factors—age, sex, tumor stage, fractionation 
scheme, treatment delivery technique, PTV size, presence of 
a pretreatment pathological diagnosis, histology or a history 
of a prior (pulmonary) malignancy—correlated significantly 
with local control, see Table 2.
TABLE 1.  Patient Characteristics of All Patients Treated with 
SABR
Characteristics N (%) or Median (Range)
Age (years) 74 (45–91)
Sex
  Male 516 (60%)
  Female 339 (40%)
Pathological diagnosis
  Yes 308 (36%)
  No 547 (64%)
WHO performance score
  0 111 (13%)
  1 446 (52%)
  2 256 (30%)
  3 38 (4%)
Charlson comorbidity index24 2 (0–11)
COPD 640 (75%)
Medically inoperable
  Yes 613 (72%)
  No 242 (28%)
SABR, stereotactic ablative radiotherapy; WHO, World Health Organization; COPD, 
chronic obstructive pulmonary disease.
TABLE 2.  Investigated Factors in Univariate Analysis for 
Correlation with Local Control
Investigated Factor p
Age 0.336
Sex 0.121
TNM stage 0.183
Fractionation scheme 0.182
Delivery technique 0.650
PTV size 0.630
Pre-SABR pathology 0.584
Histology 0.843
Prior malignancy 0.584
PTV, planning target volume; SABR, stereotactic ablative radiotherapy.
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In all but two patients, the diagnosis of a LR was based on 
findings of a CT scan, either with or without additional investi-
gations. One of the two patients without corroborative CT scan 
findings had local disease progression on serial chest X-rays 
only, but did not undergo further diagnostic tests. The second 
patient had a LR diagnosed at autopsy. Increased uptake on 
18FDG-PET scans was seen in 28 patients (61%), whereas other 
patients did not undergo 18FDG-PET scans. Unfortunately, data 
on standardized uptake values for these scans was not always 
available. A final pathological confirmation of LR was avail-
able in 18 patients (39%), with pathology obtained using trans-
thoracic biopsy (N = 7, 39%), bronchoscopy (N = 3, 17%), 
a surgical resection (N = 4, 22%), endobronchial ultrasound 
(N = 2, 11%), or after autopsy (N = 2, 11%). Of these 18 
patients, 15 had both a positive 18FDG-PET scan and patho-
logical confirmation of recurrence.
An overview of the diagnosis and management of LRs 
is given in Figure 1. Based on the available staging modalities, 
the recurrence was exclusively local in 25 patients (54%) and 
locoregional in 31 of the patients (67%). In six patients with a 
combined local and regional failure, regional failure was lim-
ited to ipsilateral hilar nodes in four patients, and two patients 
had mediastinal (N2) disease. Of 31 patients presenting with 
locoregional recurrence, only 12 were considered eligible for 
radical salvage by a multidisciplinary tumor board (MDT). Of 
these, nine patients underwent radical salvage. Five patients 
had a surgical resection, followed by either adjuvant chemo-
therapy (n = 2) or radiotherapy (n = 1). Radical nonsurgi-
cal treatments included high dose radiotherapy (n = 3) and 
chemoradiation (n = 1). Three other patients refused further 
treatment. A single patient with both a LR and a solitary 
metastasis in an adrenal gland was planned for radical treat-
ment with a lobectomy to be followed by SABR for the adrenal 
metastasis. However, due to the detection of pleural metastasis 
during surgery, the patient was subsequently referred for pal-
liative chemotherapy.
Three out of 12 patients who were considered eligible 
for radical salvage by a MDT were initially referred for SABR 
for their primary tumor as they were considered at high risk 
for surgery. At the time of a LR, these patients were again 
discussed in a MDT, and the surgical risks were considered as 
being acceptable. Of these, two patients underwent a lobec-
tomy, and one underwent a wedge resection.
The median overall survival after the diagnosis of a LR 
was 13 months (95% confidence interval: 8.6–17.4 months). 
However, patients who underwent some form of radical treatment 
(n = 10) had a median overall survival after LR of 36 months 
(mean 32 months, 95% confidence interval: 20–43 months).
A diagnosis of a SPLC was made in 79 patients (9.2%), 
at a median time of 34 months after SABR (range 3–105 
months). The actuarial cumulative incidences of SPLC at 1-, 
3-, and 5 years post-SABR were 1.9%, 11.7%, and 16.7%, 
respectively. The SPLC was located in the same lung in 37 
patients (47%) and in the same lobe in 15 patients (19%); 
all of these had pathology different from the index tumor or 
an interval exceeding 2 years. Pathological confirmation of 
the SPLC was available in only 21 patients (27%). Median 
follow-up after the diagnosis of SPLC was 23 months (range 
FIGURE 1.  Flowchart of staging and 
salvage in patients with local recur-
rences after treatment with SABR for 
early-stage lung cancer. SABR, stereo-
tactic ablative radiotherapy.
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3–105 months), and median overall survival after diagnosis 
of a SPLC was 23 months. An overview of the diagnosis and 
management of SPLC is shown in Figure 2.
DISCUSSION
The optimal follow-up schedule after SABR for early 
stage NSCLC is unclear, although the ESMO guidelines sug-
gested CT imaging every 3–6 months for a period of at least 2 or 
3 years post-SABR followed by annually thereafter.9 As the lit-
erature on long-term follow-up after SABR is relatively limited, 
we studied recurrence patterns in 855 post-SABR patients who 
were followed up for a median of 52 months. Our main find-
ing was a 5-year LR rate of 9.1%, including the cases without 
a pathological confirmation. Two thirds of patients diagnosed 
with a LR had either an isolated local- or loco-regional failure, 
indicating that the majority were potentially eligible for salvage 
therapy. However, only a minority (10 of 46 patients) finally 
underwent curative-intent treatment. The latter is likely to be 
a reflection of the fact that 72% of patients in this cohort were 
considered inoperable after assessment at a MTB at the time 
of initial presentation. The favorable median overall survival of 
36 months after radical treatment for a locoregional recurrence 
mirrors that in surgical reports on radical salvage treatment.8
Our results compare well to the recurrence rates reported 
by two prospective trials. In the RTOG 0236 trial, 55 patients 
were evaluable with a median follow-up of 4.0 years. The 
estimated primary tumor failure rate reported was 7%, and 
an additional nine patients had recurrence in the same lobe 
(16%).15 In the prospective phase II trial reported by Baumann 
et al.,16 57 patients were treated with SABR for T1-2N0M0 
NSCLC, with a median follow-up of 36 months. A local con-
trol rate of 92% at 3 years was reported.
An important finding is that three patients, who had 
been referred for SABR previously after being considered to 
be at high risk for surgery by a MDT, were considered to be 
surgical candidates when they presented with LR. This under-
lines the importance of discussing all patients with a locore-
gional recurrence in a MDT, as medical inoperability is a grey 
area, and a reflection of the risks that patients and their physi-
cians are prepared to accept in the absence of other curative 
options. Similar findings have been reported by other authors 
in patients who were initially considered inoperable, and who 
underwent SABR as initial therapy.17
Distinguishing radiological changes after SABR due 
to LRs and radiation-induced fibrosis can be quite challeng-
ing and discussion of such cases in a MDT is important in 
patients fit for salvage options.18 We recommend the follow-up 
CT scans to be reviewed by radiologists experienced in inter-
preting post-SABR findings. In case follow-up occurs out-
side of the treating center, we encourage centers to consult an 
experienced radiologist or radiation-oncologist in all cases of 
a suspected recurrence. Furthermore, ESMO guidelines rec-
ommend repeating 18FDG-PET scans if there is a suspected 
recurrence, and obtaining pathological confirmation whenever 
possible and when it is of consequence. In this series, pathol-
ogy and 18FDG-PET scans were obtained in only a minority of 
patients, largely because of the diagnosis of distant metasta-
ses, or because of a combination of age and comorbidity, and 
the views of an MDT about the lack of treatment options.
Another observation is the wide range in time to diag-
nosis of LRs. A peak in LRs was seen between 1 and 3 years 
post-SABR, but late LRs were also observed. With longer 
follow-up in this study, the median time to LR after SABR 
has increased to 22 months compared with 14.9 months as 
FIGURE 2.  Flowchart of staging and salvage in patients with a clinical diagnosis of SPLC after treatment with SABR for early 
stage NSCLC. SPLC, second primary lung cancer; SABR, stereotactic ablative radiotherapy; NSCLC, non–small-cell lung cancer.
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previously reported at our center.10 This, together with the 
observed annual rate of SPLC of 2% to 5%, suggests that 
long-term follow-up of patients is beneficial (Fig. 3). The 
rates of SPLC identified in our cohort are in agreement with 
published rates after surgery.7,19 In total, 80% of patients with 
a SPLC underwent radical salvage treatment, and because of 
the high percentage of early stage SPLC, salvage SABR for 
the SPLC was the predominant treatment. Reported outcomes 
for SABR for a SPLC have been shown to be similar to results 
of SABR for a first presentation of NSCLC.20
A key limitation of this study is that not all patients had 
a pathological diagnosis before SABR treatment. However, 
reported rates of benign disease in patients staged with 18FDG-
PET scans in the Netherlands, and who subsequently under-
went surgery for a clinical diagnosis of early stage NSCLC, 
are low.21,22
As increasingly fit patients are now undergoing SABR 
and these patients will have longer follow-up as they have less 
competing causes of mortality, more emphasis is placed on 
detection and salvage of LRs, Until now, only limited data 
on salvage procedures with curative intent, e.g., surgery, has 
been available and although these studies with limited patient 
numbers suggest it is feasible, more data on the safety and 
outcome of such procedures is needed.17,23,24
In conclusion, both the timing of LRs after SABR, as well 
a persistent risk of SPLC, serves as a rationale for long-term 
radiological follow-up using CT scans, especially in patients 
fit enough to undergo any radical treatment. Our findings sup-
port the use of a similar follow-up strategy after SABR as was 
recommended for postsurgical cases.9,25 Therefore, we recom-
mend that all patients eligible for any type of salvage undergo 6 
months follow-up CT scans for a period of 3 years post-SABR, 
followed by annual CT scans thereafter. All patients who are 
suspected of having recurrence should be discussed in an MDT.
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